Further studies on the neonatal ferret model of infection and immunity to and attenuation of human parainfluenza viruses.
Earlier we reported on the susceptibility via the intranasal route of inoculation of newborn ferrets to infection by wild and serially egg passaged parainfluenza type 3 virus. The wild type consistently induced fatal infection whereas with serial egg passage, mortality rate decreased while the degree of infectivity remained the same. This attenuation was accompanied by a change in capacity to induce interferon and decreased growth in human and primate cell cultures. The present work reports, similarly, on the susceptibility of newborn ferrets to wild and serially egg passaged parainfluenza types 1 and 2. Wild type infections caused significantly greater mortality than did egg passaged materials, although infectivity rates were approximately the same. Wild and egg passaged strains produced silent infections in adult ferrets and induced specific circulating hemagglutinin inhibiting antibodies. Newborn offspring of  dams inoculated with wild or egg passaged viruses resisted challenge with wild virus. The apparent attenuation of the wild type virus with serial egg passage viruses resisted challenge with wild virus. The apparent attenuation of the wild type virus with serial egg passage was correlated with alteration in cell culture host range and capacity  to induce interferon. The low and mid level passages of types 1 and 3 were the subject of clinical vaccination trials in man in four age groups: 18-35 years, 14-16 years and 6-12 years. The clinical and serologic results of these studies will be reported  elsewhere.
D000818:Animals; D000831:Animals, Newborn / Q000276:immunology; D000914:Antibodies, Viral / Q000032:analysis; D002335:Carnivora; D004195:Disease Models, Animal; D005260:Female; D005289:Ferrets; D006801:Humans; D007109:Immunity; D007372:Interferons / Q000032:analysis; D008168:Lung / Q000382:microbiology; D018184:Paramyxoviridae Infections / Q000276:immunology*; D018108:Respirovirus / Q000276:immunology* / Q000302:isolation & purification; D014613:Vaccines, Attenuated / Q000008:administration & dosage*; D014765:Viral Vaccines / Q000008:administration & dosage*
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines; D007372:Interferons